Generics Global Industry Guide_2017

mlig16090-06 MarketLine 28 February, 2017 248 pages

Select License

Report Description
Table of Contents
Related Reports

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the global generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The market value is evaluated at ex-factory prices.

- Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

- All currency conversions were calculated at constant average annual 2015 exchange rates.

- The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.

- Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.

- The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the global generics market by value in 2016?

- What will be the size of the global generics market in 2021?

- What factors are affecting the strength of competition in the global generics market?

- How has the market performed over the last five years?

- Who are the top competitors in the global generics market?

EXECUTIVE SUMMARY
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Global Generics
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Asia-Pacific
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Europe
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Australia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The Netherlands
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Spain
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables

1Table 1: Global generics market value: $ billion, 2012–16
2Table 2: Global generics market volume: % of total pharma volume, 2012–16
3Table 3: Global generics market geography segmentation: $ billion,2016
4Table 4: Global generics market value forecast: $ billion, 2016–21
5Table 5: Global generics market volume forecast: % of total pharma volume, 2016–21
6Table 6: Asia-Pacific generics market value: $ billion, 2012–16
7Table 7: Asia–Pacific generics market volume: % of total pharma volume, 2012–16
8Table 8: Asia–Pacific generics market geography segmentation: $ billion,2016
9Table 9: Asia-Pacific generics market value forecast: $ billion, 2016–21
10Table 10: Asia–Pacific generics market volume forecast: % of total pharma volume, 2016–21
11Table 11: Europe generics market value: $ billion, 2012–16
12Table 12: Europe generics market volume: % of total pharma volume, 2012–16
13Table 13: Europe generics market geography segmentation: $ billion,2016
14Table 14: Europe generics market value forecast: $ billion, 2016–21
15Table 15: Europe generics market volume forecast: % of total pharma volume, 2016–21
16Table 16: France generics market value: $ billion, 2012–16
17Table 17: France generics market volume: % of total pharma volume, 2012–16
18Table 18: France generics market geography segmentation: $ billion,2016
19Table 19: France generics market value forecast: $ billion, 2016–21
20Table 20: France generics market volume forecast: % of total pharma volume, 2016–21
21Table 21: France size of population (million), 2012–16
22Table 22: France gdp (constant 2005 prices, $ billion), 2012–16
23Table 23: France gdp (current prices, $ billion), 2012–16
24Table 24: France inflation, 2012–16
25Table 25: France consumer price index (absolute), 2012–16
26Table 26: France exchange rate, 2012–16
27Table 27: Germany generics market value: $ billion, 2012–16
28Table 28: Germany generics market volume: % of total pharma volume, 2012–16
29Table 29: Germany generics market geography segmentation: $ billion,2016
30Table 30: Germany generics market value forecast: $ billion, 2016–21
31Table 31: Germany generics market volume forecast: % of total pharma volume, 2016–21
32Table 32: Germany size of population (million), 2012–16
33Table 33: Germany gdp (constant 2005 prices, $ billion), 2012–16
34Table 34: Germany gdp (current prices, $ billion), 2012–16
35Table 35: Germany inflation, 2012–16
36Table 36: Germany consumer price index (absolute), 2012–16
37Table 37: Germany exchange rate, 2012–16
38Table 38: Italy generics market value: $ billion, 2012–16
39Table 39: Italy generics market volume: % of total pharma volume, 2012–16
40Table 40: Italy generics market geography segmentation: $ billion,2016
41Table 41: Italy generics market value forecast: $ billion, 2016–21
42Table 42: Italy generics market volume forecast: % of total pharma volume, 2016–21
43Table 43: Italy size of population (million), 2012–16
44Table 44: Italy gdp (constant 2005 prices, $ billion), 2012–16
45Table 45: Italy gdp (current prices, $ billion), 2012–16
46Table 46: Italy inflation, 2012–16
47Table 47: Italy consumer price index (absolute), 2012–16
48Table 48: Italy exchange rate, 2012–16
49Table 49: Japan generics market value: $ billion, 2012–16
50Table 50: Japan generics market volume: % of total pharma volume, 2012–16
51Table 51: Japan generics market geography segmentation: $ billion,2016
52Table 52: Japan generics market value forecast: $ billion, 2016–21
53Table 53: Japan generics market volume forecast: % of total pharma volume, 2016–21
54Table 54: Japan size of population (million), 2012–16
55Table 55: Japan gdp (constant 2005 prices, $ billion), 2012–16
56Table 56: Japan gdp (current prices, $ billion), 2012–16
57Table 57: Japan inflation, 2012–16
58Table 58: Japan consumer price index (absolute), 2012–16
59Table 59: Japan exchange rate, 2012–16
60Table 60: Australia generics market value: $ billion, 2012–16
61Table 61: Australia generics market volume: % of total pharma volume, 2012–16
62Table 62: Australia generics market geography segmentation: $ billion,2016
63Table 63: Australia generics market value forecast: $ billion, 2016–21
64Table 64: Australia generics market volume forecast: % of total pharma volume, 2016–21
65Table 65: Australia size of population (million), 2012–16
66Table 66: Australia gdp (constant 2005 prices, $ billion), 2012–16
67Table 67: Australia gdp (current prices, $ billion), 2012–16
68Table 68: Australia inflation, 2012–16
69Table 69: Australia consumer price index (absolute), 2012–16
70Table 70: Australia exchange rate, 2012–16
71Table 71: Canada generics market value: $ billion, 2012–16
72Table 72: Canada generics market volume: % of total pharma volume, 2012–16
73Table 73: Canada generics market geography segmentation: $ billion,2016
74Table 74: Canada generics market value forecast: $ billion, 2016–21
75Table 75: Canada generics market volume forecast: % of total pharma volume, 2016–21
76Table 76: Canada size of population (million), 2012–16
77Table 77: Canada gdp (constant 2005 prices, $ billion), 2012–16
78Table 78: Canada gdp (current prices, $ billion), 2012–16
79Table 79: Canada inflation, 2012–16
80Table 80: Canada consumer price index (absolute), 2012–16
81Table 81: Canada exchange rate, 2012–16
82Table 82: China generics market value: $ billion, 2012–16
83Table 83: China generics market volume: % of total pharma volume, 2012–16
84Table 84: China generics market geography segmentation: $ billion,2016
85Table 85: China generics market value forecast: $ billion, 2016–21
86Table 86: China generics market volume forecast: % of total pharma volume, 2016–21
87Table 87: China size of population (million), 2012–16
88Table 88: China gdp (constant 2005 prices, $ billion), 2012–16
89Table 89: China gdp (current prices, $ billion), 2012–16
90Table 90: China inflation, 2012–16
91Table 91: China consumer price index (absolute), 2012–16
92Table 92: China exchange rate, 2012–16
93Table 93: Netherlands generics market value: $ billion, 2012–16
94Table 94: Netherlands generics market volume: % of total pharma volume, 2012–16
95Table 95: Netherlands generics market geography segmentation: $ billion,2016
96Table 96: Netherlands generics market value forecast: $ billion, 2016–21
97Table 97: Netherlands generics market volume forecast: % of total pharma volume, 2016–21
98Table 98: Netherlands size of population (million), 2012–16
99Table 99: Netherlands gdp (constant 2005 prices, $ billion), 2012–16
100Table 100: Netherlands gdp (current prices, $ billion), 2012–16
101Table 101: Netherlands inflation, 2012–16
102Table 102: Netherlands consumer price index (absolute), 2012–16
103Table 103: Netherlands exchange rate, 2012–16
104Table 104: Spain generics market value: $ billion, 2012–16
105Table 105: Spain generics market volume: % of total pharma volume, 2012–16
106Table 106: Spain generics market geography segmentation: $ billion,2016
107Table 107: Spain generics market value forecast: $ billion, 2016–21
108Table 108: Spain generics market volume forecast: % of total pharma volume, 2016–21
109Table 109: Spain size of population (million), 2012–16
110Table 110: Spain gdp (constant 2005 prices, $ billion), 2012–16
111Table 111: Spain gdp (current prices, $ billion), 2012–16
112Table 112: Spain inflation, 2012–16
113Table 113: Spain consumer price index (absolute), 2012–16
114Table 114: Spain exchange rate, 2012–16
115Table 115: United Kingdom generics market value: $ billion, 2012–16
116Table 116: United Kingdom generics market volume: % of total pharma volume, 2012–16
117Table 117: United Kingdom generics market geography segmentation: $ billion,2016
118Table 118: United Kingdom generics market value forecast: $ billion, 2016–21
119Table 119: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
120Table 120: United Kingdom size of population (million), 2012–16
121Table 121: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
122Table 122: United Kingdom gdp (current prices, $ billion), 2012–16
123Table 123: United Kingdom inflation, 2012–16
124Table 124: United Kingdom consumer price index (absolute), 2012–16
125Table 125: United Kingdom exchange rate, 2012–16
126Table 126: United States generics market value: $ billion, 2012–16
127Table 127: United States generics market volume: % of total pharma volume, 2012–16
128Table 128: United States generics market geography segmentation: $ billion,2016
129Table 129: United States generics market value forecast: $ billion, 2016–21
130Table 130: United States generics market volume forecast: % of total pharma volume, 2016–21
131Table 131: United States size of population (million), 2012–16
132Table 132: United States gdp (constant 2005 prices, $ billion), 2012–16
133Table 133: United States gdp (current prices, $ billion), 2012–16
134Table 134: United States inflation, 2012–16
135Table 135: United States consumer price index (absolute), 2012–16
136Table 136: United States exchange rate, 2012–15
137Table 137: Allergan plc: key facts
138Table 138: Allergan plc: key financials ($)
139Table 139: Allergan plc: key financial ratios
140Table 140: Mylan Inc.: key facts
141Table 141: Mylan Inc.: key financials ($)
142Table 142: Mylan Inc.: key financial ratios
143Table 143: Sandoz International GmbH: key facts
144Table 144: Teva Pharmaceutical Industries Limited: key facts
145Table 145: Teva Pharmaceutical Industries Limited: key financials ($)
146Table 146: Teva Pharmaceutical Industries Limited: key financial ratios
147Table 147: Sun Pharmaceutical Industries Ltd.: key facts
148Table 148: Sun Pharmaceutical Industries Ltd.: key financials ($)
149Table 149: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
150Table 150: Sun Pharmaceutical Industries Ltd.: key financial ratios
151Table 151: Sanofi SA: key facts
152Table 152: Sanofi SA: key financials ($)
153Table 153: Sanofi SA: key financials (€)
154Table 154: Sanofi SA: key financial ratios
155Table 155: Les Laboratoires Servier: key facts
156Table 156: STADA Arzneimittel AG: key facts
157Table 157: STADA Arzneimittel AG: key financials ($)
158Table 158: STADA Arzneimittel AG: key financials (€)
159Table 159: STADA Arzneimittel AG: key financial ratios
160Table 160: Daiichi Sankyo Co., Ltd.: key facts
161Table 161: Daiichi Sankyo Co., Ltd.: key financials ($)
162Table 162: Daiichi Sankyo Co., Ltd.: key financials (¥)
163Table 163: Daiichi Sankyo Co., Ltd.: key financial ratios
164Table 164: Sawai Pharmaceutical Co., Ltd.: key facts
165Table 165: Sawai Pharmaceutical Co., Ltd.: key financials ($)
166Table 166: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
167Table 167: Sawai Pharmaceutical Co., Ltd.: key financial ratios
168Table 168: Aspen Pharmacare Holdings Ltd: key facts
169Table 169: Aspen Pharmacare Holdings Ltd: key financials ($)
170Table 170: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
171Table 171: Aspen Pharmacare Holdings Ltd: key financial ratios
172Table 172: Apotex, Inc.: key facts
173Table 173: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
174Table 174: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
175Table 175: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
176Table 176: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
177Table 177: Esteve Group: key facts

List of Figures

1Figure 1: Global generics market value: $ billion, 2012–16
2Figure 2: Global generics market volume: % of total pharma volume, 2012–16
3Figure 3: Global generics market geography segmentation: % share, by value,2016
4Figure 4: Global generics market value forecast: $ billion, 2016–21
5Figure 5: Global generics market volume forecast: % of total pharma volume, 2016–21
6Figure 6: Forces driving competition in the global generics market,2016
7Figure 7: Drivers of buyer power in the global generics market,2016
8Figure 8: Drivers of supplier power in the global generics market,2016
9Figure 9: Factors influencing the likelihood of new entrants in the global generics market,2016
10Figure 10: Factors influencing the threat of substitutes in the global generics market,2016
11Figure 11: Drivers of degree of rivalry in the global generics market,2016
12Figure 12: Asia-Pacific generics market value: $ billion, 2012–16
13Figure 13: Asia–Pacific generics market volume: % of total pharma volume, 2012–16
14Figure 14: Asia–Pacific generics market geography segmentation: % share, by value,2016
15Figure 15: Asia-Pacific generics market value forecast: $ billion, 2016–21
16Figure 16: Asia–Pacific generics market volume forecast: % of total pharma volume, 2016–21
17Figure 17: Forces driving competition in the generics market in Asia-Pacific,2016
18Figure 18: Drivers of buyer power in the generics market in Asia-Pacific,2016
19Figure 19: Drivers of supplier power in the generics market in Asia-Pacific,2016
20Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific,2016
21Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific,2016
22Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific,2016
23Figure 23: Europe generics market value: $ billion, 2012–16
24Figure 24: Europe generics market volume: % of total pharma volume, 2012–16
25Figure 25: Europe generics market geography segmentation: % share, by value,2016
26Figure 26: Europe generics market value forecast: $ billion, 2016–21
27Figure 27: Europe generics market volume forecast: % of total pharma volume, 2016–21
28Figure 28: Forces driving competition in the generics market in Europe,2016
29Figure 29: Drivers of buyer power in the generics market in Europe,2016
30Figure 30: Drivers of supplier power in the generics market in Europe,2016
31Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe,2016
32Figure 32: Factors influencing the threat of substitutes in the generics market in Europe,2016
33Figure 33: Drivers of degree of rivalry in the generics market in Europe,2016
34Figure 34: France generics market value: $ billion, 2012–16
35Figure 35: France generics market volume: % of total pharma volume, 2012–16
36Figure 36: France generics market geography segmentation: % share, by value,2016
37Figure 37: France generics market value forecast: $ billion, 2016–21
38Figure 38: France generics market volume forecast: % of total pharma volume, 2016–21
39Figure 39: Forces driving competition in the generics market in France,2016
40Figure 40: Drivers of buyer power in the generics market in France,2016
41Figure 41: Drivers of supplier power in the generics market in France,2016
42Figure 42: Factors influencing the likelihood of new entrants in the generics market in France,2016
43Figure 43: Factors influencing the threat of substitutes in the generics market in France,2016
44Figure 44: Drivers of degree of rivalry in the generics market in France,2016
45Figure 45: Germany generics market value: $ billion, 2012–16
46Figure 46: Germany generics market volume: % of total pharma volume, 2012–16
47Figure 47: Germany generics market geography segmentation: % share, by value,2016
48Figure 48: Germany generics market value forecast: $ billion, 2016–21
49Figure 49: Germany generics market volume forecast: % of total pharma volume, 2016–21
50Figure 50: Forces driving competition in the generics market in Germany,2016
51Figure 51: Drivers of buyer power in the generics market in Germany,2016
52Figure 52: Drivers of supplier power in the generics market in Germany,2016
53Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany,2016
54Figure 54: Factors influencing the threat of substitutes in the generics market in Germany,2016
55Figure 55: Drivers of degree of rivalry in the generics market in Germany,2016
56Figure 56: Italy generics market value: $ billion, 2012–16
57Figure 57: Italy generics market volume: % of total pharma volume, 2012–16
58Figure 58: Italy generics market geography segmentation: % share, by value,2016
59Figure 59: Italy generics market value forecast: $ billion, 2016–21
60Figure 60: Italy generics market volume forecast: % of total pharma volume, 2016–21
61Figure 61: Forces driving competition in the generics market in Italy,2016
62Figure 62: Drivers of buyer power in the generics market in Italy,2016
63Figure 63: Drivers of supplier power in the generics market in Italy,2016
64Figure 64: Factors influencing the likelihood of new entrants in the generics market in Italy,2016
65Figure 65: Factors influencing the threat of substitutes in the generics market in Italy,2016
66Figure 66: Drivers of degree of rivalry in the generics market in Italy,2016
67Figure 67: Japan generics market value: $ billion, 2012–16
68Figure 68: Japan generics market volume: % of total pharma volume, 2012–16
69Figure 69: Japan generics market geography segmentation: % share, by value,2016
70Figure 70: Japan generics market value forecast: $ billion, 2016–21
71Figure 71: Japan generics market volume forecast: % of total pharma volume, 2016–21
72Figure 72: Forces driving competition in the generics market in Japan,2016
73Figure 73: Drivers of buyer power in the generics market in Japan,2016
74Figure 74: Drivers of supplier power in the generics market in Japan,2016
75Figure 75: Factors influencing the likelihood of new entrants in the generics market in Japan,2016
76Figure 76: Factors influencing the threat of substitutes in the generics market in Japan,2016
77Figure 77: Drivers of degree of rivalry in the generics market in Japan,2016
78Figure 78: Australia generics market value: $ billion, 2012–16
79Figure 79: Australia generics market volume: % of total pharma volume, 2012–16
80Figure 80: Australia generics market geography segmentation: % share, by value,2016
81Figure 81: Australia generics market value forecast: $ billion, 2016–21
82Figure 82: Australia generics market volume forecast: % of total pharma volume, 2016–21
83Figure 83: Forces driving competition in the generics market in Australia,2016
84Figure 84: Drivers of buyer power in the generics market in Australia,2016
85Figure 85: Drivers of supplier power in the generics market in Australia,2016
86Figure 86: Factors influencing the likelihood of new entrants in the generics market in Australia,2016
87Figure 87: Factors influencing the threat of substitutes in the generics market in Australia,2016
88Figure 88: Drivers of degree of rivalry in the generics market in Australia,2016
89Figure 89: Canada generics market value: $ billion, 2012–16
90Figure 90: Canada generics market volume: % of total pharma volume, 2012–16
91Figure 91: Canada generics market geography segmentation: % share, by value,2016
92Figure 92: Canada generics market value forecast: $ billion, 2016–21
93Figure 93: Canada generics market volume forecast: % of total pharma volume, 2016–21
94Figure 94: Forces driving competition in the generics market in Canada,2016
95Figure 95: Drivers of buyer power in the generics market in Canada,2016
96Figure 96: Drivers of supplier power in the generics market in Canada,2016
97Figure 97: Factors influencing the likelihood of new entrants in the generics market in Canada,2016
98Figure 98: Factors influencing the threat of substitutes in the generics market in Canada,2016
99Figure 99: Drivers of degree of rivalry in the generics market in Canada,2016
100Figure 100: China generics market value: $ billion, 2012–16
101Figure 101: China generics market volume: % of total pharma volume, 2012–16
102Figure 102: China generics market geography segmentation: % share, by value,2016
103Figure 103: China generics market value forecast: $ billion, 2016–21
104Figure 104: China generics market volume forecast: % of total pharma volume, 2016–21
105Figure 105: Forces driving competition in the generics market in China,2016
106Figure 106: Drivers of buyer power in the generics market in China,2016
107Figure 107: Drivers of supplier power in the generics market in China,2016
108Figure 108: Factors influencing the likelihood of new entrants in the generics market in China,2016
109Figure 109: Factors influencing the threat of substitutes in the generics market in China,2016
110Figure 110: Drivers of degree of rivalry in the generics market in China,2016
111Figure 111: Netherlands generics market value: $ billion, 2012–16
112Figure 112: Netherlands generics market volume: % of total pharma volume, 2012–16
113Figure 113: Netherlands generics market geography segmentation: % share, by value,2016
114Figure 114: Netherlands generics market value forecast: $ billion, 2016–21
115Figure 115: Netherlands generics market volume forecast: % of total pharma volume, 2016–21
116Figure 116: Forces driving competition in the generics market in the Netherlands,2016
117Figure 117: Drivers of buyer power in the generics market in the Netherlands,2016
118Figure 118: Drivers of supplier power in the generics market in the Netherlands,2016
119Figure 119: Factors influencing the likelihood of new entrants in the generics market in the Netherlands,2016
120Figure 120: Factors influencing the threat of substitutes in the generics market in the Netherlands,2016
121Figure 121: Drivers of degree of rivalry in the generics market in the Netherlands,2016
122Figure 122: Spain generics market value: $ billion, 2012–16
123Figure 123: Spain generics market volume: % of total pharma volume, 2012–16
124Figure 124: Spain generics market geography segmentation: % share, by value,2016
125Figure 125: Spain generics market value forecast: $ billion, 2016–21
126Figure 126: Spain generics market volume forecast: % of total pharma volume, 2016–21
127Figure 127: Forces driving competition in the generics market in Spain,2016
128Figure 128: Drivers of buyer power in the generics market in Spain,2016
129Figure 129: Drivers of supplier power in the generics market in Spain,2016
130Figure 130: Factors influencing the likelihood of new entrants in the generics market in Spain,2016
131Figure 131: Factors influencing the threat of substitutes in the generics market in Spain,2016
132Figure 132: Drivers of degree of rivalry in the generics market in Spain,2016
133Figure 133: United Kingdom generics market value: $ billion, 2012–16
134Figure 134: United Kingdom generics market volume: % of total pharma volume, 2012–16
135Figure 135: United Kingdom generics market geography segmentation: % share, by value,2016
136Figure 136: United Kingdom generics market value forecast: $ billion, 2016–21
137Figure 137: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
138Figure 138: Forces driving competition in the generics market in the United Kingdom,2016
139Figure 139: Drivers of buyer power in the generics market in the United Kingdom,2016
140Figure 140: Drivers of supplier power in the generics market in the United Kingdom,2016
141Figure 141: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom,2016
142Figure 142: Factors influencing the threat of substitutes in the generics market in the United Kingdom,2016
143Figure 143: Drivers of degree of rivalry in the generics market in the United Kingdom,2016
144Figure 144: United States generics market value: $ billion, 2012–16
145Figure 145: United States generics market volume: % of total pharma volume, 2012–16
146Figure 146: United States generics market geography segmentation: % share, by value,2016
147Figure 147: United States generics market value forecast: $ billion, 2016–21
148Figure 148: United States generics market volume forecast: % of total pharma volume, 2016–21
149Figure 149: Forces driving competition in the generics market in the United States,2016
150Figure 150: Drivers of buyer power in the generics market in the United States,2016
151Figure 151: Drivers of supplier power in the generics market in the United States,2016
152Figure 152: Factors influencing the likelihood of new entrants in the generics market in the United States,2016
153Figure 153: Factors influencing the threat of substitutes in the generics market in the United States,2016
154Figure 154: Drivers of degree of rivalry in the generics market in the United States,2016
155Figure 155: Allergan plc: revenues & profitability
156Figure 156: Allergan plc: assets & liabilities
157Figure 157: Mylan Inc.: revenues & profitability
158Figure 158: Mylan Inc.: assets & liabilities
159Figure 159: Teva Pharmaceutical Industries Limited: revenues & profitability
160Figure 160: Teva Pharmaceutical Industries Limited: assets & liabilities
161Figure 161: Sun Pharmaceutical Industries Ltd.: revenues & profitability
162Figure 162: Sun Pharmaceutical Industries Ltd.: assets & liabilities
163Figure 163: Sanofi SA: revenues & profitability
164Figure 164: Sanofi SA: assets & liabilities
165Figure 165: STADA Arzneimittel AG: revenues & profitability
166Figure 166: STADA Arzneimittel AG: assets & liabilities
167Figure 167: Daiichi Sankyo Co., Ltd.: revenues & profitability
168Figure 168: Daiichi Sankyo Co., Ltd.: assets & liabilities
169Figure 169: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
170Figure 170: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
171Figure 171: Aspen Pharmacare Holdings Ltd: revenues & profitability
172Figure 172: Aspen Pharmacare Holdings Ltd: assets & liabilities
173Figure 173: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
174Figure 174: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities